Profile image
Visiting Professorial Fellow

Dr Sarah Pett

Therapeutic and Vaccine Research Program
Phone
+61 (0)2 9385 0900
E-mail
spett@kirby.unsw.edu.au
Scott K; Chappell E; Mostafa A; Volokha A; Najmi N; Ebeid F; Posokhova S; Sikandar R; Vasylyev M; Zulfiqar S; Kaminskyi V; Pett S; Malyuta R; Karpus R; Ayman Y; Ahmed RHM; Hamid S; El-Sayed MH; Gibb D; Judd A; Collins IJ, 2024, 'Acceptability of hepatitis C screening and treatment during pregnancy in pregnant women in Egypt, Pakistan, and Ukraine: A cross-sectional survey.', Clin Liver Dis (Hoboken), 23, pp. e0140, http://dx.doi.org/10.1097/CLD.0000000000000140
2024
Anagnostou N; Archuleta S; Athan E; Barina L; Best E; Bloomfield M; Bostock J; Botheras C; Bowen A; Britton P; Burden H; Campbell A; Carter H; Cheng M; Chew KL; Chong IRLM; Coombs G; Daley P; Daneman N; Davies J; Davis J; Dishon-Benattar Y; Dotel R; Dunlop A; Flack F; Flanagan K; Foo H; Ghanem-Zoubi N; Giulieri S; Goodman A; Grant J; Gregson D; Guy S; Gwee A; Hardy E; Henderson A; Heriot G; Howden B; Hudson F; Johnstone J; Kalimuddin S; de Kretser D; Kwa A; Lee T; Legg A; Lewis R; Llewelyn M; Lumley T; Lye D; MacFadden D; Mahar R; Malhame I; Marks M; Marsh J; Martinello M; Matthews G; McArthur C; McGlothlin A; McKew G; McMullan B; McQuilten Z; Milliken E; Mora J; Morpeth S; Murthy S; Nourse C; O'Sullivan M; Paterson D; Paul M; Petersiel N; Petrella L; Pett S; Price D; Roberts J; Robinson JO; Rogers B; Saville B; Scarborough M; Scheetz M; Scheuerman O; Schwartz K; Smith S; Snelling T; Soares M; Sommerville C; Stewardson A; Stone N; Sud A; Tilley R; Tong S; Turner R; Underwood J; van Hal S; Voss L; Walls G; Webb R; Webb S; Whiteway L; Wilson H; Wuerz T; Yahav D, 2023, 'The Staphylococcus aureus Network Adaptive Platform Trial Protocol: New Tools for an Old Foe (vol 75, pg 2027, 2022)', CLINICAL INFECTIOUS DISEASES, http://dx.doi.org/10.1093/cid/ciac730
2023
Polizzotto M; Nordwall J; Babiker AG; Phillips A; Vock DM; Eriobu N; Khwaghe V; Paredes R; Mateu L; Ramachandruni S; Narang R; Jain MK; Lazarte SM; Baker JV; Frosch AEP; Poulakou G; Syrigos KN; Arnoczy GS; McBride NA; Robinson PA; Sarafian F; Bhagani S; Taha HS; Benfield T; Liu STH; Antoniadou A; Jensen JUS; Kalomenidis I; Susilo A; Hariadi P; Jensen TO; Morales-Rull JL; Helleberg M; Meegada S; Johansen IS; Canario D; Fernández-Cruz E; Metallidis S; Shah A; Sakurai A; Koulouris N; Trotman R; Weintrob AC; Podlekareva D; Hadi U; Lloyd KM; Røge BT; Saito S; Sweerus K; Malin JJ; Lübbert C; Muñoz J; Cummings MJ; Losso MH; Turner D; Shaw-Saliba K; Highbarger H; Lallemand P; Rehman T; Dewar R; Gerry N; Arlinda D; Chang CC; Grund B; Holbrook M; Holley HP; Hudson F; McNay LA; Murray DD; Pett S; Shaughnessy M; Smolskis MC; Touloumi G; Wright M; Doyle MK; Popik S; Hall C; Ramanathan R; Cao H; Mondou E; Willis T; Thakuria JV; Yel L; Higgs E; Kan VL; Lundgren JD; Neaton JD; Lane HC; Amos L; Carlsen A; Carter A; Davis B; Denning E; DuChene A; Engen N; Grandits G; Harrison M; Kaiser P; Meger S; Murray T, 2022, 'Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial', The Lancet, 399, pp. 530 - 540, http://dx.doi.org/10.1016/S0140-6736(22)00101-5
2022
Murray DD; Babiker AG; Baker JV; Barkauskas CE; Brown SM; Chang CC; Davey VJ; Gelijns AC; Ginde AA; Grund B; Higgs E; Hudson F; Kan VL; Lane HC; Murray TA; Paredes R; Parmar MKB; Pett S; Phillips AN; Polizzotto MN; Reilly C; Sandkovsky U; Sharma S; Teitelbaum M; Thompson BT; Young BE; Neaton JD; Lundgren JD, 2022, 'Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3)', Clinical Trials, 19, pp. 52 - 61, http://dx.doi.org/10.1177/17407745211049829
2022
Douin DJ; Siegel L; Grandits G; Phillips A; Aggarwal NR; Baker J; Brown SM; Chang CC; Goodman AL; Grund B; Higgs ES; Hough CL; Murray DD; Paredes R; Parmar M; Pett S; Polizzotto MN; Sandkovsky U; Self WH; Young BE; Babiker AG; Davey VJ; Kan V; Gelijns AC; Matthews G; Thompson BT; Lane HC; Neaton JD; Lundgren JD; Ginde AA; Meintjes GA; Armstrong W; Glidden D; Maldonado Y; Murray BE; Ray SC; Rolla VC; Saloojee H; Tsiatis AA; Volberding PA; Kimmelman J; Hunsberger S, 2022, 'Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery', American Journal of Respiratory and Critical Care Medicine, 206, pp. 730 - 739, http://dx.doi.org/10.1164/rccm.202112-2836OC
2022
Rogers AJ; Wentworth D; Phillips A; Shaw-Saliba K; Dewar RL; Aggarwal NR; Babiker AG; Chang W; Dharan NJ; Davey VJ; Higgs ES; Gerry N; Ginde AA; Hayanga JWA; Highbarger H; Highbarger JL; Jain MK; Kan V; Kim K; Lallemand P; Leshnower BG; Lutaakome JK; Matthews G; Mourad A; Mylonakis E; Natarajan V; Padilla ML; Pandit LM; Paredes R; Pett S; Ramachandruni S; Rehman MT; Sherman BT; Files DC; Brown SM; Matthay MA; Thompson BT; Neaton JD; Lane HC; Lundgren JD, 2022, 'The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19', Annals of Internal Medicine, 175, pp. 1401 - 1410, http://dx.doi.org/10.7326/M22-0924
2022
Mylonakis E, 2022, 'Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 A Randomized Controlled Trial', Annals of Internal Medicine, 175, pp. 1266 - 1274, http://dx.doi.org/10.7326/M22-1503
2022
Grundmann A; Hardwick M; Wu C-H; Semple M; Böhning D; Pett S; Michael B; Thomas R; Galea I, 2022, 'Prevention of neurological complications during COVID-19: a retrospective analysis of the ISARIC4C national cohort', Journal of Neurology, Neurosurgery & Psychiatry, 93, pp. e2.135 - e2.135, http://dx.doi.org/10.1136/jnnp-2022-abn2.22
2022
Burns JE; Stirrup O; Waters L; Dunn D; Gilson R; Pett SL, 2022, 'No overall impact on rate of weight gain with integrase inhibitor-containing regimens in antiretroviral-naïve adults.', HIV Med, 23, pp. 294 - 300, http://dx.doi.org/10.1111/hiv.13186
2022
Murray DD; Babiker AG; Baker J; Barkauskas CE; Brown SM; Chang CC; Davey VJ; Gelijns AC; Ginde AA; Grund B; Higgs E; Hudson F; Kan VL; Lane HC; Murray TA; Paredes R; Parmar MKB; Pett S; Phillips AN; Polizzotto MN; Reilly C; Sandkovsky U; Sharma S; Teitelbaum M; Thompson BT; Young BE; Neaton JD; Lundgren JD, 2021, 'Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3)', CLINICAL TRIALS, 19, pp. 52 - 61, http://dx.doi.org/10.1177/17407745211049829
2021
Butler M; Tamborska A; Wood GK; Ellul M; Thomas RH; Galea I; Pett S; Singh B; Solomon T; Pollak TA; Michael BD; Nicholson TR, 2021, 'Considerations for causality assessment of neurological and neuropsychiatric complications of SARS-CoV-2 vaccines: from cerebral venous sinus thrombosis to functional neurological disorder.', J Neurol Neurosurg Psychiatry, 92, pp. 1144 - 1151, http://dx.doi.org/10.1136/jnnp-2021-326924
2021
Pett SL; Spyer M; Haddow LJ; Nhema R; Benjamin LA; Najjuka G; Bilima S; Daud I; Musoro G; Kitabalwa J; Selemani G; Kandie S; Cornelius KM; Katemba C; Berkley JA; Hassan AS; Kityo C; Hakim J; Heyderman RS; Gibb DM; Walker AS, 2021, 'Benefits of enhanced infection prophylaxis at antiretroviral therapy initiation by cryptococcal antigen status', AIDS, 35, pp. 585 - 594, http://dx.doi.org/10.1097/QAD.0000000000002781
2021
Cooke GS; Pett S; McCabe L; Jones C; Gilson R; Verma S; Ryder SD; Collier JD; Barclay ST; Ala A; Bhagani S; Nelson M; Ch'Ng C; Stone B; Wiselka M; Forton D; McPherson S; Halford R; Nguyen D; Smith D; Ansari A; Dennis E; Hudson F; Barnes EJ; Walker AS, 2021, 'Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C.', Wellcome Open Res, 6, pp. 93, http://dx.doi.org/10.12688/wellcomeopenres.16594.2
2021
Wendt CH; Castro-Pearson S; Proper J; Pett S; Griffin TJ; Kan V; Carbone J; Koulouris N; Reilly C; Neaton JD; INSIGHT FLU003 Plus Study Group , 2021, 'Metabolite profiles associated with disease progression in influenza infection.', PLoS One, 16, pp. e0247493, http://dx.doi.org/10.1371/journal.pone.0247493
2021
Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP, 2021, 'The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.', Lancet Glob Health, 9, pp. e620 - e627, http://dx.doi.org/10.1016/S2214-109X(21)00025-5
2021
Ray STJ; Abdel-Mannan O; Sa M; Fuller C; Wood GK; Pysden K; Yoong M; McCullagh H; Scott D; McMahon M; Thomas N; Taylor M; Illingworth M; McCrea N; Davies V; Whitehouse W; Zuberi S; Guthrie K; Wassmer E; Shah N; Baker MR; Tiwary S; Tan HJ; Varma U; Ram D; Avula S; Enright N; Hassell J; Ross Russell AL; Kumar R; Mulholland RE; Pett S; Galea I; Thomas RH; Lim M; Hacohen Y; Solomon T; Griffiths MJ; Michael BD; Kneen R; CoroNerve study group , 2021, 'Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK: a prospective national cohort study.', Lancet Child Adolesc Health, 5, pp. 631 - 641, http://dx.doi.org/10.1016/S2352-4642(21)00193-0
2021
Ross Russell AL; Hardwick M; Jeyanantham A; White LM; Deb S; Burnside G; Joy HM; Smith CJ; Pollak TA; Nicholson TR; Davies NWS; Manji H; Easton A; Ray S; Zandi MS; Coles JP; Menon DK; Varatharaj A; McCausland B; Ellul MA; Thomas N; Breen G; Keddie S; Lunn MP; Burn JPS; Quattrocchi G; Dixon L; Rice CM; Pengas G; Al-Shahi Salman R; Carson A; Joyce EM; Turner MR; Benjamin LA; Solomon T; Kneen R; Pett S; Thomas RH; Michael BD; Galea I, 2021, 'Spectrum, risk factors and outcomes of neurological and psychiatric complications of COVID-19: a UK-wide cross-sectional surveillance study.', Brain Commun, 3, pp. fcab168, http://dx.doi.org/10.1093/braincomms/fcab168
2021
Cooke GS; Pett S; McCabe L; Jones C; Gilson R; Verma S; Ryder SD; Collier JD; Barclay ST; Ala A; Bhagani S; Nelson M; Ch’Ng CL; Stone B; Wiselka M; Forton D; McPherson S; Halford R; Nguyen D; Smith D; Ansari MA; Ainscough H; Dennis E; Hudson F; Barnes EJ; Walker AS, 2021, 'Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT', Efficacy and Mechanism Evaluation, 8, pp. 1 - 90, http://dx.doi.org/10.3310/eme08170
2021
Burns JE; Stöhr W; Kinloch-De Loes S; Fox J; Clarke A; Nelson M; Thornhill J; Babiker A; Frater J; Pett SL; Fidler S, 2021, 'Tolerability of four-drug antiretroviral combination therapy in primary HIV-1 infection.', HIV Med, 22, pp. 770 - 774, http://dx.doi.org/10.1111/hiv.13118
2021
Hung R; Patel N; Fox J; Cosgrove C; Pett SL; Burns F; Ustianowski A; Rosenvinge M; Bhagani S; Dusheiko G; Childs K; Post FA; GEN-AFRICA study group , 2021, 'Prevalence of HIV/hepatitis B and HIV/hepatitis C coinfection among people of East, South, Central and West African ancestry in the United Kingdom.', AIDS, 35, pp. 1701 - 1704, http://dx.doi.org/10.1097/QAD.0000000000002929
2021
Judd A; Collins IJ; Pett S; Gibb DM, 2021, 'Labour pains: eliminating HCV in women and children.', Lancet Gastroenterol Hepatol, 6, pp. 150 - 151, http://dx.doi.org/10.1016/S2468-1253(20)30373-3
2021
Flower B; McCabe L; Le Ngoc C; Le Manh H; Le Thanh P; Dang Trong T; Vo Thi T; Vu Thi Kim H; Nguyen Tat T; Phan Thi Hong D; Nguyen Thi Chau A; Dinh Thi T; Tran Thi Tuyet N; Tarning J; Kingsley C; Kestelyn E; Pett SL; Thwaites G; Nguyen Van VC; Smith D; Barnes E; Ansari MA; Turner H; Rahman M; Walker AS; Day J; Cooke GS, 2021, 'High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study.', Open Forum Infect Dis, 8, pp. ofab267, http://dx.doi.org/10.1093/ofid/ofab267
2021
Cooke GS; Pett S; McCabe L; Jones C; Gilson R; Verma S; Ryder SD; Collier JD; Barclay ST; Ala A; Bhagani S; Nelson M; Ch'Ng C; Stone B; Wiselka M; Forton D; McPherson S; Halford R; Nguyen D; Smith D; Ansari A; Dennis E; Hudson F; Barnes EJ; Walker AS, 2021, 'Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C', Wellcome Open Research, 6, pp. 93 - 93, http://dx.doi.org/10.12688/wellcomeopenres.16594.2
2021
Nugent D; Stirrup O; Pett S; Panwar K; Checchi M; Mesher D; Soldan K; Beddows S; Gilson R, 2021, 'Performance of human papillomavirus DNA detection in residual specimens taken for Chlamydia trachomatis and Neisseria gonorrhoeae nucleic acid amplification testing in men who have sex with men.', Sex Transm Infect, 97, pp. 541 - 546, http://dx.doi.org/10.1136/sextrans-2020-054702
2021
Alagaratnam J; Stöhr W; Toombs J; Heslegrave A; Zetterberg H; Gisslén M; Pett S; Nelson M; Clarke A; Nwokolo N; Johnson MA; Khan M; Hanke T; Kopycinski J; Dorrell L; Fox J; Kinloch S; Underwood J; Pace M; Frater J; Winston A; Fidler S; RIVER trial study group , 2021, 'No evidence of neuronal damage as measured by neurofilament light chain in a HIV cure study utilising a kick-and-kill approach.', J Virus Erad, 7, pp. 100056, http://dx.doi.org/10.1016/j.jve.2021.100056
2021
Burns JE; Stirrup OT; Dunn D; Runcie-Unger I; Milinkovic A; Candfield S; Lukha H; Severn A; Waters L; Edwards S; Gilson R; Pett SL, 2020, 'No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV', AIDS, 34, pp. 109 - 114, http://dx.doi.org/10.1097/QAD.0000000000002379
2020
Noor NM; Pett SL; Esmail H; Crook AM; Vale CL; Sydes MR; Parmar MKB, 2020, 'Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings.', F1000Res, 9, pp. 1109, http://dx.doi.org/10.12688/f1000research.26253.2
2020
Noor NM; Pett SL; Esmail H; Crook AM; Vale CL; Sydes MR; Parmar MKB, 2020, 'Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings', F1000Research, 9, pp. 1109 - 1109, http://dx.doi.org/10.12688/f1000research.26253.1
2020
Varatharaj A; Thomas N; Ellul MA; Davies NWS; Pollak TA; Tenorio EL; Sultan M; Easton A; Breen G; Zandi M; Coles JP; Manji H; Al-Shahi Salman R; Menon DK; Nicholson TR; Benjamin LA; Carson A; Smith C; Turner MR; Solomon T; Kneen R; Pett SL; Galea I; Thomas RH; Michael BD; CoroNerve Study Group , 2020, 'Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study.', Lancet Psychiatry, 7, pp. 875 - 882, http://dx.doi.org/10.1016/S2215-0366(20)30287-X
2020
Ellul M; Varatharaj A; Nicholson TR; Pollak TA; Thomas N; Easton A; Zandi MS; Manji H; Solomon T; Carson A; Turner MR; Kneen R; Galea I; Pett S; Thomas RH; Michael BD; CoroNerve Steering Committee , 2020, 'Defining causality in COVID-19 and neurological disorders.', J Neurol Neurosurg Psychiatry, 91, pp. 811 - 812, http://dx.doi.org/10.1136/jnnp-2020-323667
2020
Fidler S; Stöhr W; Pace M; Dorrell L; Lever A; Pett S; Kinloch-de Loes S; Fox J; Clarke A; Nelson M; Thornhill J; Khan M; Fun A; Bandara M; Kelly D; Kopycinski J; Hanke T; Yang H; Bennett R; Johnson M; Howell B; Barnard R; Wu G; Kaye S; Wills M; Babiker A; Frater J; RIVER trial study group , 2020, 'Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial.', Lancet, 395, pp. 888 - 898, http://dx.doi.org/10.1016/S0140-6736(19)32990-3
2020
McCabe L; White IR; Chau NVV; Barnes E; Pett SL; Cooke GS; Walker AS; SEARCH investigators , 2020, 'The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam.', Trials, 21, pp. 413, http://dx.doi.org/10.1186/s13063-020-04350-x
2020
Varatharaj A; Pollak TA; Nicholson TR; Coles JP; Benjamin LA; Carson A; Thomas RH; Michael BD; study authors , 2020, 'Characterising neuropsychiatric disorders in patients with COVID-19 - Authors' reply.', Lancet Psychiatry, 7, pp. 934 - 935, http://dx.doi.org/10.1016/S2215-0366(20)30420-X
2020
Davey RT; Fernández-Cruz E; Markowitz N; Pett S; Babiker AG; Wentworth D; Khurana S; Engen N; Gordin F; Jain MK; Kan V; Polizzotto MN; Riska P; Ruxrungtham K; Temesgen Z; Lundgren J; Beigel JH; Lane HC; Neaton JD; Butts J; Denning E; DuChene A; Krum E; Harrison M; Meger S; Peterson R; Quan K; Shaughnessy M; Thompson G; Vock D; Metcalf J; Dewar R; Rehman T; Natarajan V; McConnell R; Flowers E; Smith K; Hoover M; Coyle EM; Munroe D; Aagaard B; Pearson M; Cursley A; Webb H; Hudson F; Russell C; Sy A; Purvis C; Jackson B; Collaco-Moraes Y; Carey D; Robson R; Sánchez A; Finley E; Conwell D; Losso MH; Gambardella L; Abela C; Lopez P; Alonso H; Touloumi G; Gioukari V; Anagnostou O; Avihingsanon A; Pussadee K; Ubolyam S; Omotosho B; Solórzano C; Petersen T; Vysyaraju K; Rizza SA; Whitaker JA; Nahra R; Baxter J; Coburn P; Gardner EM; Scott JA; Faber L; Pastor E; Makohon L; MacArthur RA; Hillman LM; Farrough MJ; Polenakovik HM; Clark LA; Colon RJ; Kunisaki KM; DeConcini M; Johnson SA; Wolfe CR; Mkumba L; Carbonneau JY; Morris A; Fitzpatrick ME; Kessinger CJ; Salata RA; Arters KA; Tasi CM; Panos RJ; Lach LA, 2019, 'Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial', The Lancet Respiratory Medicine, 7, pp. 951 - 963, http://dx.doi.org/10.1016/S2213-2600(19)30253-X
2019
Peterson I; Ntsui N; Jambo K; Kelly C; Huwa J; Afran L; Tatuene JK; Pett S; Romain Henrion MY; Van Oosterhout J; Heyderman RS; Mwandumba H; Benjamin LA; Angus B; Connor M; Dwivedi R; Haddow L; Heikinheimo-Connell T; Joekes E; Kandoole V; Nyrienda M; Malisita K; Mallewa J; Soliman EZ; Solomon T, 2019, 'Evaluating the reactivation of herpesviruses and inflammation as cardiovascular and cerebrovascular risk factors in antiretroviral therapy initiators in an African HIV-infected population (RHICCA): A protocol for a longitudinal cohort study', BMJ Open, 9, http://dx.doi.org/10.1136/bmjopen-2018-025576
2019
Castillo-Mancilla JR; Phillips AN; Neaton JD; Neuhaus J; Sharma S; Baker JV; Collins S; Mannheimer S; Pett S; Touzeau-Römer V; Polizzotto MN; Lundgren JD; Gardner EM, 2019, 'Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study', Journal of the International AIDS Society, 22, http://dx.doi.org/10.1002/jia2.25297
2019
Polizzotto M; Van Bockel D; Law C; Roberts J; Buckland G; Just S; Comben S; Hillman R; Gilson R; Pett S; Poynten M; Law M; Kelleher A; Emery S, 2019, 'Clearance of HPV Anal Premalignant Lesions and Modulation of Systemic Immune Responses to HPV Oncogenes with Low Dose Pomalidomide', Annals of Oncology, 30, pp. xi35 - xi35, http://dx.doi.org/10.1093/annonc/mdz451.005
2019
Alagaratnam J; Stohr W; Toombes J; Zetterberg H; Pett S; Nelson M; Kinloch S; Clarke A; Nwokolo N; Johnson M; Fox J; Hanke T; Kopycinski J; Dorrell L; Babiker A; Frater J; Winston A; Fidler S, 2019, 'No evidence of neuroaxonal injury following latency reversal with vorinostat and HIV-1 specific vaccination in the RIVER trial', Journal of Virus Eradication, 5, pp. 22 - 23, http://dx.doi.org/10.1016/s2055-6640(20)31066-9
2019
Siika A; McCabe L; Bwakura-Dangarembizi M; Kityo C; Mallewa J; Berkley J; Maitland K; Griffiths A; Baleeta K; Mudzingwa S; Abach J; Nathoo K; Thomason MJ; Prendergast AJ; Walker AS; Gibb DM; Mugyenyi P; Musiime V; Wavamunno P; Nambi E; Ocitti P; Ndigendawani M; Kemigisa M; Acen J; Olebo D; Mpamize G; Amone A; Okweny D; Mbonye A; Nambaziira F; Rweyora A; Kangah M; Kabaswahili V; Abongomera G; Omongin J; Aciro I; Philliam A; Arach B; Ocung E; Amone G; Miles P; Adong C; Tumsuiime C; Kidega P; Otto B; Apio F; Mukuye A; Abwola M; Ssennono F; Baliruno D; Tuhirwe S; Namisi R; Kigongo F; Kikyonkyo D; Mushahara F; Tusiime J; Musiime A; Nankya A; Atwongyeire D; Sirikye S; Mula S; Noowe N; Lugemwa A; Kasozi M; Mwebe S; Atwine L; Senkindu T; Natuhurira T; Katemba C; Ninsiima E; Acaku M; Kyomuhangi J; Ankunda R; Tukwasibwe D; Ayesiga L; Hakim J; Reid A; Chidziva E; Mhute T; Tinago GC; Bhiri J; Phiri M; Steamer J; Nhema R; Warambwa C; Musoro G; Mutsai S; Nemasango B; Moyo C; Chitongo S; Rashirai K; Vhembo S; Mlambo B; Nkomani S; Ndemera B; Willard M; Berejena C; Musodza Y; Matiza P; Mudenge B, 2018, 'Late Presentation with HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial', Clinical Infectious Diseases, 66, pp. S140 - S146, http://dx.doi.org/10.1093/cid/cix1142
2018
Post FA; Szubert AJ; Prendergast AJ; Johnston V; Lyall H; Fitzgerald F; Musiime V; Musoro G; Chepkorir P; Agutu C; Mallewa J; Rajapakse C; Wilkes H; Hakim J; Mugyenyi P; Sarah Walker A; Gibb DM; Pett SL; Kityo C; Wavamunno P; Nambi E; Ocitti P; Ndigendawani M; Portal F; Kabahenda S; Kemigisa M; Acen J; Olebo D; Mpamize G; Amone A; Okweny D; Mbonye A; Nambaziira F; Rweyora A; Kangah M; Kabaswahili V; Abach J; Abongomera G; Omongin J; Aciro I; Philliam A; Arach B; Ocung E; Amone G; Miles P; Adong C; Tumsuiime C; Kidega P; Otto B; Apio F; Baleeta K; Mukuye A; Abwola M; Ssennono F; Baliruno D; Tuhirwe S; Namisi R; Kigongo F; Kikyonkyo D; Mushahara F; Tusiime J; Musiime A; Nankya A; Atwongyeire D; Sirikye S; Mula S; Noowe N; Lugemwa A; Kasozi M; Mwebe S; Atwine L; Senkindu T; Natuhurira T; Katemba C; Ninsiima E; Acaku M; Kyomuhangi J; Ankunda R; Tukwasibwe D; Ayesiga L; Nathoo K; Bwakura-Dangarembizi M; Reid A; Chidziva E; Mhute T; Tinago GC; Bhiri J; Mudzingwa S; Phiri M; Steamer J; Nhema R; Warambwa C; Mutsai S; Nemasango B; Moyo C; Chitongo S; Rashirai K; Vhembo S; Mlambo B; Nkomani S, 2018, 'Causes and Timing of Mortality and Morbidity among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial', Clinical Infectious Diseases, 66, pp. S132 - S139, http://dx.doi.org/10.1093/cid/cix1141
2018
Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Madero JS; Belloso W; Tu E; Silk D; Kelleher A; Harrigan R; Clark A; Sugiura W; Wolff M; Gill J; Gatell J; Clarke A; Ruxrungtham K; Prazuck T; Kaiser R; Woolley I; Alberto Arnaiz J; Cooper D; Rockstroh JK; Mallon P; Emery S; Fisher M; Rockstroh J; Stellbrink J; Merlin K; Yeung J; Fsadni B; Marks K; Suzuki K; Rismanto N; Salomon H; Rubio AE; Chibo D; Birch C; Swenson L; Chan D; Berg T; Obermeier M; Schuelter E; Aragon SS; Luebke N; Coughlan S; Dean J; Iwatani Y; Teran GR; Avila S; Sirivichayakul S; Naphassanant M; Ubolyam S; Kaye S; Land S; Walker S; Haubrich R; DeJesus E; Berthon-Jones N; Espinosa N; Courtney-Vega K; Absar N; Haskelberg H; Robson R; Donaldson A; Guelman D; Gambardella L; Valdovinos M; Arnaiz J; Beleta H; Ramos N; Targa M; Späth B; Boesecke C; Engelhardt A; Perry N; Beckthold B; Drummond F; Lefevre E; Corr S; Grant C; Lupo S; Peroni L; Sanchez M; De Paz Sierra M; Viloria G; Parlante A; Bissio E; Luchetti P; Confalonieri V; Warley E; Vieni I; Vilas C; Zarate A; Mayer G; Elliot J; Hagenauer M; Kelley M; Bloch M; Cooper D, 2018, 'Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study', HIV Medicine, 19, pp. 65 - 71, http://dx.doi.org/10.1111/hiv.12532
2018
Powers JH; Bacci ED; Leidy NK; Poon JL; Stringer S; Memoli MJ; Han A; Fairchok MP; Coles C; Owens J; Chen WJ; Arnold JC; Danaher PJ; Lalani T; Burgess TH; Millar EV; Ridore M; Hernández A; Rodríguez-Zulueta P; Ortega-Gallegos H; Galindo-Fraga A; Ruiz-Palacios GM; Pett S; Fischer W; Gillor D; Macias LM; DuVal A; Rothman R; Dugas A; Guerrero ML, 2018, 'Performance of the inFLUenza Patient-Reported Outcome (FLU-PRO) diary in patients with influenza-like illness (ILI)', PLoS ONE, 13, http://dx.doi.org/10.1371/journal.pone.0194180
2018
Mallewa J; Szubert AJ; Mugyenyi P; Chidziva E; Thomason MJ; Chepkorir P; Abongomera G; Baleeta K; Etyang A; Warambwa C; Melly B; Mudzingwa S; Kelly C; Agutu C; Wilkes H; Nkomani S; Musiime V; Lugemwa A; Pett SL; Bwakura-Dangarembizi M; Prendergast AJ; Gibb DM; Walker AS; Berkley JA; Kityo C; Wavamunno P; Nambi E; Ocitti P; Ndigendawani M; Kabahenda S; Kemigisa M; Acen J; Olebo DF; Mpamize G; Amone A; Okweny D; Mbonye A; Nambaziira F; Rweyora A; Kangah M; Kabaswahili B; Abach J; Omongin J; Aciro I; Philliam A; Arach B; Ocung E; Amone G; Miles P; Adong C; Tumsuiime C; Kidega P; Otto B; Apio F; Mukuye A; Abwola M; Ssennono F; Baliruno D; Tuhirwe S; Namisi R; Kigongo F; Kikyonkyo D; Mushahara F; Tusiime J; Musiime A; Nankya A; Atwongyeire D; Sirikye S; Myalo S; Noowe N; Kasozi M; Mwebe S; Atwine L; Senkindu T; Natuhurira I; Katemba C; Ninsiima E; Acaku M; Kyomuhangi J; Ankunda R; Tukwasibwe D; Ayesiga L; Hakim J; Nathoo K; Reid A; Mhute T; Tinago G; Bhiri J; Phiri M; Steamer J; Nhema R; Musoro G; Mutsai S; Nemasango B; Moyo C; Chitongo S; Rashirai K; Vhembo S; Mlambo B; Ndemera B, 2018, 'Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial', The Lancet HIV, 5, pp. e231 - e240, http://dx.doi.org/10.1016/S2352-3018(18)30038-9
2018
Powers JH; Bacci ED; Guerrero ML; Leidy NK; Stringer S; Kim K; Memoli MJ; Han A; Fairchok MP; Chen WJ; Arnold JC; Danaher PJ; Lalani T; Ridoré M; Burgess TH; Millar EV; Hernández A; Rodríguez-Zulueta P; Smolskis MC; Ortega-Gallegos H; Pett S; Fischer W; Gillor D; Macias LM; DuVal A; Rothman R; Dugas A; Ruiz-Palacios GM, 2018, 'Reliability, Validity, and Responsiveness of InFLUenza Patient-Reported Outcome (FLU-PRO©) Scores in Influenza-Positive Patients', Value in Health, 21, pp. 210 - 218, http://dx.doi.org/10.1016/j.jval.2017.04.014
2018
Kityo C; Szubert AJ; Siika A; Heyderman R; Bwakura-Dangarembizi M; Lugemwa A; Mwaringa S; Griffiths A; Nkanya I; Kabahenda S; Wachira S; Musoro G; Rajapakse C; Etyang T; Abach J; Spyer MJ; Wavamunno P; Nyondo-Mipando L; Chidziva E; Nathoo K; Klein N; Hakim J; Gibb DM; Walker AS; Pett SL, 2018, 'Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial', PLoS Medicine, 15, http://dx.doi.org/10.1371/journal.pmed.1002706
2018
Simonsen L; Higgs E; Taylor RJ; Wentworth D; Cozzi-Lepri A; Pett S; Dwyer DE; Davey R; Lynfield R; Losso M; Morales K; Glesby MJ; Weckx J; Carey D; Lane C; Lundgren J; Emery S, 2018, 'Using clinical research networks to assess severity of an emerging influenza pandemic', Clinical Infectious Diseases, 67, pp. 341 - 349, http://dx.doi.org/10.1093/cid/ciy088
2018
Pett SL; Kunisaki KM; Wentworth D; Griffin TJ; Kalomenidis I; Nahra R; Sanchez RM; Hodgson SW; Ruxrungtham K; Dwyer D; Davey RT; Wendt CH; Lundgren J; Jansson P; Pearson M; Aagaard B; Hudson F; Bennet R; Pacciarini F; Angus B; Paton N; Collaco Moraes Y; Cooper D; Emery S; Courtney-Rogers D; Robson R; Gordin F; Sanchez A; Standridge B; Vjecha M; Moricz A; Delfino M; Belloso W; Losso M; Tillmann K; Touloumi G; Gioukari V; Anagnostou O; La Rosa A; Saenz MJ; Lopez P; Herrero P; Portas B; Kaewon P; Ubolyam S; Brekke K; Campbell M; Denning E; DuChene A; Engen N; George M; Harrison M; Neaton JD; Nelson R; Quan SF; Schultz T; Baxter J; Brown S; Hoover M; Beigel J; Dewar R; Gover E; McConnell R; Metcalf J; Natarajan V; Rehman T; Voell J; Dwyer DE; Kok J; Uyeki T; Munroe D; Paez A; Bertrand M; Temesgen Z; Rizza S; Wolfe C; Carbonneau J; Novak R; Schwarber M; Polenakovik H; Clark L; Patil N; Riska P; Omotosho J; Faber L; Markowitz N; Glesby M; Ham K; Parenti D; Simon G; Coburn P; Freiberg M; Koerbel G; Dharan N; Paez-Quinde M; Gunter J; Beilke M; Lu Z; Gunderson E; Baker J, 2018, 'Increased indoleamine-2,3-dioxygenase activity is associated with poor clinical outcome in adults hospitalized with influenza in the INSIGHT FLU003Plus study', Open Forum Infectious Diseases, 5, pp. ofx228, http://dx.doi.org/10.1093/ofid/ofx228
2018
Vanderven HA; Wragg K; Ana-Sosa-Batiz F; Kristensen AB; Jegaskanda S; Wheatley AK; Wentworth D; Wines BD; Hogarth PM; Rockman S; Kent SJ; INSIGHT FLU005 Pilot Study Writing Group , 2018, 'Anti-Influenza Hyperimmune Immunoglobulin Enhances Fc-Functional Antibody Immunity During Human Influenza Infection.', J Infect Dis, 218, pp. 1383 - 1393, http://dx.doi.org/10.1093/infdis/jiy328
2018
Castillo-Mancilla JR; Phillips AN; Neaton JD; Neuhaus J; Collins S; Mannheimer S; Pett S; Touzeau-Römer V; Polizzotto MN; Lundgren JD; Gardner EM, 2018, 'Association of Suboptimal Antiretroviral Therapy Adherence with Inflammation in Virologically Suppressed Individuals Enrolled in the SMART Study', Open Forum Infectious Diseases, 5, http://dx.doi.org/10.1093/ofid/ofx275
2018
Peterson RL; Vock DM; Powers JH; Emery S; Cruz EF; Hunsberger S; Jain MK; Pett S; Neaton JD, 2017, 'Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization', Clinical Trials, 14, pp. 264 - 276, http://dx.doi.org/10.1177/1740774517697919
2017
Hakim J; Musiime V; Szubert AJ; Mallewa J; Siika A; Agutu C; Walker S; Pett SL; Bwakura-Dangarembizi M; Lugemwa A; Kaunda S; Karoney M; Musoro G; Kabahenda S; Nathoo K; Maitland K; Griffiths A; Thomason MJ; Kityo C; Mugyenyi P; Prendergast AJ; Walker AS; Gibb DM; REALITY Trial Team , 2017, 'Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa.', N Engl J Med, 377, pp. 233 - 245, http://dx.doi.org/10.1056/NEJMoa1615822
2017
Kelly ML; Pinto AN; Suan D; Marriott D; Cooper DA; Pett SL, 2017, 'Managing two decades of visceral leishmaniasis and HIV co-infection: A case report that illustrates the urgent research needs in the field', Sexual Health, 14, pp. 286 - 288, http://dx.doi.org/10.1071/SH16036
2017
Fox-Lewis A; Brima N; Muniina P; Grant AD; Edwards SG; Miller RF; Pett SL, 2016, 'Tuberculosis screening in patients with HIV: An audit against UK national guidelines to assess current practice and the effectiveness of an electronic tuberculosis-screening prompt', International Journal of STD and AIDS, 27, pp. 901 - 905, http://dx.doi.org/10.1177/0956462416628355
2016
Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Madero JS; Belloso W; Tu E; Silk D; Kelleher A; Harrigan R; Clark A; Sugiura W; Wolff M; Gill J; Gatell J; Fisher M; Clarke A; Ruxrungtham K; Prazuck T; Kaiser R; Woolley I; Arnaiz JA; Cooper D; Rockstroh JK; Mallon P; Emery S; Cooper D, 2016, 'Maraviroc, as a switch option, in HIV-1-infected individuals with stable, well-controlled HIV replication and R5-tropic virus on their first Nucleoside/Nucleotide reverse transcriptase inhibitor plus ritonavir-boosted protease inhibitor regimen: Week 48 Results of the randomized, multicenter March study', Clinical Infectious Diseases, 63, pp. 122 - 132, http://dx.doi.org/10.1093/cid/ciw207
2016
2016, 'Oral abstracts of the 21st International AIDS Conference 18-22 July 2016, Durban, South Africa.', J Int AIDS Soc, 19, pp. 21264, http://dx.doi.org/10.7448/IAS.19.6.21264
2016
Powers JH; Bacci ED; Leidy NK; Stringer S; Kim K; Memoli MJ; Han A; Fairchok MP; Chen W; Arnold JC; Danaher PJ; Lalani T; Hansen EA; Ridore M; Burgess TH; Millar EV; Hernández A; Rodríguez-Zulueta P; Ortega-Gallegos H; Galindo-Fraga A; Ruiz-Palacios GM; Pett S; Fischer W; Gillor D; Macias LM; DuVal A; Rothman R; Dugas A; Guerrero ML, 2016, 'Evaluation of the Performance Properties of the Influenza Patient-Reported Outcomes Instrument (Flu-Pro)', Value in Health, 19, pp. A220 - A221, http://dx.doi.org/10.1016/j.jval.2016.03.1186
2016
Ryder S; Pett S; Cooke GS, 2016, 'Genotype 4 and the global challenge of hepatitis C treatment', The Lancet Gastroenterology and Hepatology, 1, pp. 3 - 4, http://dx.doi.org/10.1016/S2468-1253(16)30006-1
2016
Mocroft A; Lundgren JD; Ross M; Law M; Reiss P; Kirk O; Smith C; Wentworth D; Neuhaus J; Fux CA; Moranne O; Morlat P; Johnson MA; Ryom L; Powderly B; Shortman N; Moecklinghoff C; Reilly G; Franquet X; Sabin CA; Phillips A; Weber R; Pradier C; d'Arminio Monforte A; Dabis F; El-Sadr WM; De Wit S; Kamara D; Tverland J; Mansfeld M; Nielsen J; Raben D; Salbøl Brandt R; Rickenbach M; Fanti I; Krum E; Hillebregt M; Geffard S; Sundström A; Delforge M; Fontas E; Torres F; McManus H; Wright S; Kjær J; Sjøl A; Meidahl P; Helweg-Larsen J; Schmidt Iversen J; Kesselring AM; Friis-Møller N; Kowalska J; Sabin C; Bruyand M; Kamara DA; Bower M; Fätkenheuer G; Donald A; Grulich A; Prins JM; Kuijpers TW; Scherpbier HJ; van der Meer JTM; Wit FWMN; Godfried MH; van der Poll T; Nellen FJB; Geerlings SE; van Vugt M; Pajkrt D; Bos JC; Wiersinga WJ; van der Valk M; Goorhuis A; Hovius JW; van Eden J; Henderiks A; van Hes AMH; Mutschelknauss M; Nobel HE; Pijnappel FJJ; Westerman AM; Jurriaans S; Back NKT; Zaaijer HL; Berkhout B; Cornelissen MTE; Schinkel CJ; Thomas XV; van den Berge M; Stegeman A; Baas S; Hage de Looff L; Versteeg D; Pronk MJH; Ammerlaan HSM; Korsten-Vorstermans EMHM; de Munnik ES; Jansz AR; Tjhie J; Finlayson R; Cooper D; Carr A; Bloch M; Harrod M; Pett S; Petoumenos K; Gold J; Medland N; Sullivan J; Han A, 2015, 'Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study', PLoS Medicine, 12, pp. e1001809, http://dx.doi.org/10.1371/journal.pmed.1001809
2015
Borges ÁH; O'Connor JL; Phillips AN; Rönsholt FF; Pett S; Vjecha MJ; French MA; Lundgren JD, 2015, 'Factors Associated with Plasma IL-6 Levels during HIV Infection', Journal of Infectious Diseases, 212, pp. 585 - 595, http://dx.doi.org/10.1093/infdis/jiv123
2015
Madhavi V; Ana-Sosa-Batiz FE; Jegaskanda S; Center RJ; Winnall WR; Parsons MS; Ananworanich J; Cooper DA; Kelleher AD; Hsu D; Pett S; Stratov I; Kramski M; Kent SJ, 2015, 'Antibody-dependent effector functions against HIV decline in subjects receiving antiretroviral therapy', Journal of Infectious Diseases, 211, pp. 529 - 538, http://dx.doi.org/10.1093/infdis/jiu486
2015
Lundgren J; Babiker A; Gordin F; Emery S; Fätkenheuer G; Molina JM; Wood R; Neaton JD; Agan BK; Alston-Smith B; Arenas-Pinto A; Arribas JR; Baker JV; Baxter J; Belloso WH; Brekke K; Brew B; Brobst SW; Burman W; Carey C; Clark R; Cooper DA; Davey RT; De La Rosa G; Denning ET; Dolan M; Dore G; Duprez D; Emanuel E; Grady C; Grund B; Hirschel B; Hoen B; Hudson F; Johnson MA; Kambili C; Klingman K; Kunisaki KM; Landay A; Ledergerber B; Lehrman SN; Martinez A; Meger S; Misar K; Mitsuyasu RT; Mocroft A; Munroe D; Norton M; Palmer RC; Pett SL; Phillips A; Pillay D; Porter D; Price RW; Proschan M; Rappoport C; Reiss P; Renjifo B; Robertson K; Rockstroh J; Rodriguez G; Rooney JF; Ross MJ; Schechter M; Schwarze S; Seekins D; Sharma S; Snowden W; Telenti A; Tryon J; van Wyk J; Vjecha MJ; Wright E; Cooper D, 2015, 'Why START? Reflections that led to the conduct of this large long-term strategic HIV trial', HIV Medicine, 16, pp. 1 - 9, http://dx.doi.org/10.1111/hiv.12227
2015
Amin J; Becker S; Belloso W; Boffito M; Cooper D; Crabtree-Ramirez B; Duncombe C; Foulkes S; Hill A; Jessen H; Kumar S; Lee MP; Nwizu C; Read T; Rooney J; Schaffer K; Shahar E; Winston A; Wolff M; Young B; Abela C; Avihingsanon A; Boyd M; Carey D; Clarke A; Courtney-Vega K; Delfino M; Donaldson A; Emery S; Espinosa N; Johannesen T; Lin E; Losso M; Moricz A; Pett S; Phanupak P; Puls R; Pussadee K; Sutheerasak P; Tomlins L; Ubolyam S; bin Raja Azwa RIS; Bissio E; Calanni L; Chetchotisakd P; Doong N; Elliott J; Gazzard B; Kelly M; Laplume H; del Carmen Luna N; Lupo S; Messina OG; Mohapi L; Moore R; Nolan D; Orrell C; Perez C; Phanuphak P; Rockstroh J; Rowling D; Supparatpinyo K; Smith D; Villanueva JA; Vlahakis E; Kelleher T; Cunningham P; Merlin K; Yeung J; Shaik A; Fsadni B; Carrera A; Lograsso M; Gulick R; Dunn D; Dolan M; Emery S; Kelleher A, 2015, 'Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study', The Lancet Infectious Diseases, 15, pp. 793 - 802, http://dx.doi.org/10.1016/S1473-3099(15)70060-5
2015
Baker JV; Engen NW; Huppler Hullsiek K; Stephan C; Jain MK; Munderi P; Pett S; Duprez D; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group , 2015, 'Assessment of arterial elasticity among HIV-positive participants with high CD4 cell counts: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.', HIV Med, 16 Suppl 1, pp. 109 - 118, http://dx.doi.org/10.1111/hiv.12239
2015
Murray DD; Suzuki K; Law M; Trebicka J; Neuhaus J; Wentworth D; Johnson M; Vjecha MJ; Kelleher AD; Emery S; Aagaard B; Aragon E; Arnaiz J; Borup L; Clotet B; Dragsted U; Fau A; Gey D; Grarup J; Hengge U; Herrero P; Jansson P; Jensen B; Jensen K; Juncher H; Lopez P; Lundgren JD; Matthews C; Mollerup D; Pearson M; Phillips A; Reilev S; Tillmann K; Varea S; Angus B; Babiker A; Cordwell B; Darbyshire J; Dodds W; Fleck S; Horton J; Hudson F; Moraes Y; Pacciarini F; Palfreeman A; Paton N; Smith N; Van Hooff F; Bebchuk J; Collins G; Denning E; DuChene A; Fosdick L; Harrison M; Herman-Lamin K; Krum E; Larson G; Neaton J; Nelson R; Quan K; Quan S; Schultz T; Thompson G; Wyman N; Carey C; Chan F; Cooper D; Courtney-Rodgers D; Drummond F; Harrod M; Jacoby S; Kearney L; Lin E; Pett S; Robson R; Seneviratne N; Stewart M; Watts E; Finley E; Gordin F; Sánchez A; Standridge B; Belloso W; Davey R; Duprez D; Gatell J; Hoy J; Lifson A; Pederson C; Perez G; Price R; Prineas R; Rhame F; Sampson J; Worley J; Modlin J; Beral V; Chaisson R; Fleming T; Hill C; Bloch M; Cooper D; Konecny P; Carr A; Medland N; Sullivan J; Han A, 2015, 'Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection: A case control study', PLoS ONE, 10, pp. e0139981, http://dx.doi.org/10.1371/journal.pone.0139981
2015
Amin J; Becker S; Belloso W; Boffito M; Cooper D; Crabtree-Ramirez B; Duncombe C; Emery S; Foulkes S; Hill A; Jessen H; Kumar S; Lee MP; Losso M; Nwizu C; Phanuphak P; Ripin D; Read T; Rooney J; Schaffer K; Shahar E; Winston A; Wolff M; Young B; Abela C; Boyd M; Carey D; Clarke A; Courtney-Vega K; Dazo C; Delfino M; Donaldson A; Espinosa N; Johannesen T; Kaew-On P; Lin E; Moricz A; Taylor J; Phanupak P; Puls RL; Pussadee K; Sutheerasak P; Tomkins L; Ubolyam S; Shah Bin Raja Azwa RI; Bissio E; Calanni L; Casiro A; Chetchotisakd P; Contarelli J; Doong N; Elliott J; Gazzard B; Kelly M; Del Carmen Luna N; Lupo S; Messina OG; Mohapi L; Moore R; Nolan D; Orrell C; Perez C; Pett S; Rockstroh J; Supparatpinyo K; Smith D; Villanueva JA; Vlahakis E; Kelleher T; Cunningham P; Merlin K; Yeung J; Shaik A; Fsadni B; Carrera A; Lograsso M; Gulick R; Crabtree-Ramiraz B; Winston E; Dunn D; Dolan M; Cooper D; Kelleher A, 2014, 'Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): A randomised, double-blind, placebo-controlled, non-inferiority trial', The Lancet, 383, pp. 1474 - 1482, http://dx.doi.org/10.1016/S0140-6736(13)62187-X
2014
Pinto A; Pett S; Jackson Y, 2014, 'Identifying chagas disease in Australia: An emerging challenge for general practitioners', Australian Family Physician, 43, pp. 440 - 442
2014
Seddiki N; Cook L; Hsu DC; Phetsouphanh C; Brown K; Xu Y; Kerr SJ; Cooper DA; Munier CML; Pett S; Ananworanich J; Zaunders J; Kelleher AD, 2014, 'Human antigen-specific CD4+CD25+CD134+CD39+ T cells are enriched for regulatory T cells and comprise a substantial proportion of recall responses', European Journal of Immunology, 44, pp. 1644 - 1661, http://dx.doi.org/10.1002/eji.201344102
2014
Borges AH; O'Connor JL; Phillips AN; Rönsholt FF; Pett S; Vjecha MJ; French MA; Lundgren JD, 2014, 'Determinants of IL-6 levels during HIV infection.', J Int AIDS Soc, 17, pp. 19482, http://dx.doi.org/10.7448/IAS.17.4.19482
2014
Hsu DC; Kerr SJ; Thongpaeng P; Iampornsin T; Pett SL; Zaunders JJ; Avihingsanon A; Ubolyam S; Ananworanich J; Kelleher AD; Cooper DA, 2014, 'Incomplete restoration of Mycobacterium tuberculosis-specific-CD4 T cell responses despite antiretroviral therapy', Journal of Infection, 68, pp. 344 - 354, http://dx.doi.org/10.1016/j.jinf.2013.11.016
2014
Jackson Y; Pinto A; Pett S, 2014, 'Chagas disease in Australia and New Zealand: Risks and needs for public health interventions', Tropical Medicine and International Health, 19, pp. 212 - 218, http://dx.doi.org/10.1111/tmi.12235
2014
Phetsouphanh C; Xu Y; Bailey M; Pett S; Zaunders J; Seddiki N; Kelleher AD, 2014, 'Ratios of effector to central memory antigen-specific CD4 + T cells vary with antigen exposure in HIV+ patients', Immunology and Cell Biology, 92, pp. 384 - 388, http://dx.doi.org/10.1038/icb.2013.101
2014
Leenders FJ; Amin J; Bloch M; Pett SL; Marriott D; Carr AD, 2013, 'Skeletal muscle toxicity associated with raltegravir-based combination antiretroviral therapy in HIV-infected adults', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 62, pp. 525 - 533, http://dx.doi.org/10.1097/QAI.0b013e3182832578
2013
Hsu DC; Kerr SJ; Iampornsin T; Pett SL; Avihingsanon A; Thongpaeng P; Zaunders JJ; Ubolyam S; Ananworanich J; Kelleher AD; Cooper DA, 2013, 'Restoration of CMV-Specific-CD4 T Cells with ART Occurs Early and Is Greater in Those with More Advanced Immunodeficiency', PLoS ONE, 8, http://dx.doi.org/10.1371/journal.pone.0077479
2013
Bjerk SM; Baker J; Emery S; Neuhaus JA; Angus BJ; Gordin F; Pett SL; Stephan C; Kunisaki KM, 2013, 'Biomarkers and Bacterial Pneumonia Risk in Patients with Treated HIV Infection: A Case-Control Study', PLoS ONE, 8, pp. e56249, http://dx.doi.org/10.1371/journal.pone.0056249
2013
Davey Jr R; Lynfield R; Dwyer DE; Losso MH; Cozzi-Lepri A; Wentworth D; Lane HC; Dewar RL; Pett SL; Uyeki TM; Angus BJ; Cummins NW; Lundgren JD; Neaton JD, 2013, 'The Association between Serum Biomarkers and Disease Outcome in Influenza A(H1N1)pdm09 Virus Infection: Results of Two International Observational Cohort Studies', PLoS ONE, 8, pp. e57121, http://dx.doi.org/10.1371/journal.pone.0057121
2013
Tu E; Swenson LC; Land S; Pett S; Emery S; Marks K; Kelleher AD; Kaye S; Kaiser R; Schuelter E; Harrigan R, 2013, 'Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc switch collaborative study', Journal of Clinical Microbiology, 51, pp. 2063 - 2071, http://dx.doi.org/10.1128/JCM.00510-13
2013
Babiker AG; Emery S; Faetkenheuer G; Gordin FM; Grund B; Lundgren JD; Neaton JD; Pett SL; Phillips A; Touloumi G; Vjecha MJ, 2012, 'Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study', CLINICAL TRIALS, pp. 1 - 32, http://dx.doi.org/10.1177/1740774512440342
2012
Botes LP; Pett SL; Carr AD; Marriott D; Cooper DA; Matthews G; Carbone S; Kumaradevan N; Mchugh L; Hillman R, 2012, 'Anal cytological abnormalities are poor predictors of high-grade intraepithelial neoplasia amongst HIV-positive men who have sex with men.', Sexual Health, 10, pp. 9 - 17, http://dx.doi.org/10.1071/SH11135
2012
Boesecke C; Pett SL, 2012, 'Clinical studies with chemokine receptor-5 (CCR5)-inhibitors', Current opinion in HIV & AIDS, 7, pp. 456 - 462, http://dx.doi.org/10.1097/COH.0b013e328356e933
2012
Carey DL; Pett SL; Bloch M; Wand H; MacRae K; Beileiter K; Ray J; Boyd MA; Emery S; Cooper DA, 2012, 'A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 60, pp. 143 - 149, http://dx.doi.org/10.1097/QAI.0b013e318252f97e
2012
Hsu DC; Zaunders J; Plit ML; Leeman C; Ip S; Iampornsin T; Pett SL; Bailey MR; Amin J; Ubolyam S; Avihingsanon A; Ananworanich J; Ruxrungtham K; Cooper DA; Kelleher AD, 2012, 'A novel assay detecting recall response to Mycobacterium tuberculosis: Comparison with existing assays', Tuberculosis, 92, pp. 321 - 327, http://dx.doi.org/10.1016/j.tube.2012.03.008
2012
Dwyer DE; Davey R; Losso MH; Lynfield R; Cozzi-Lepri A; Gey D; Herman-Lamin K; Hoppe A; Lane ; Lundgren JD; Neaton JD; Pett SL; Standridge B; Uyeki M; Wentworth D, 2011, 'Surveillance of illness associated with pandemic (H1N1) 2009 virus infection among adults using a global clinical site netwok approach: The INSIGHT FLU 002 and FLU 003 studies', Vaccine, 29, pp. B56 - B62
2011
Botes LP; Jin F; Bourne CP; Pett SL; Marriott D; Carr AD; Cooper DA; Matthews G; Brew BJ; Hillman R, 2011, 'Participants' perspectives of self-collected anal cytological swabs', Sexual Health, 8, pp. 257 - 258, http://search.informit.com.au/documentSummary;dn=026957204834502;res=IELHEA
2011
Wallace BJ; Tan KB; Pett SL; Cooper DA; Kossard S; Whitfeld M, 2011, 'Enfuvirtide injection site reactions: A clinical and histopathological appraisal', Australasian Journal of Dermatology, 52, pp. 19 - 26, http://dx.doi.org/10.1111/j.1440-0960.2010.00717.x
2011
Pett SL; Carey C; Lin E; Wentworth D; Lazovski J; Miro J; Gordin F; Angus B; Rodriguez-Barradas M; Rubio R; Tambussi G; Cooper DA; Emery S, 2011, 'Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT)', HIV Medicine, 12, pp. 219 - 227, http://dx.doi.org/10.1111/j.1468-1293.2010.00875.x
2011
Hillman R; Pett SL; Marriott D; Carr AD; Cooper DA; Matthews GV; Brew BJ; Milliken S; Botes LP, 2011, 'Participants' perspectives of high resolution anoscopy', Sexual Health, 8, pp. 255 - 256, http://search.informit.com.au/documentSummary;dn=026919938891985;res=IELHEA
2011
Neuhaus J; Jacobs DR; Baker JV; Calmy A; Duprez D; La Rosa A; Kuller LH; Pett SL; Ristola M; Ross M; Shlipak MG; Tracy R; Neaton JD, 2010, 'Markers of inflammation, coagulation and renal function are elevated in adults with HIV infection', Journal of Infectious Diseases, 201, pp. 1788 - 1795
2010
Pett SL; Zaunders J; Bailey M; Murray JM; Macrae K; Emery S; Cooper DA; Kelleher AD, 2010, 'A novel Chemokine-Receptor-5 (CCR5) blocker, SCH532706, has differential effects on CCR5+CD4+ and CCR5+CD8+ T cell numbers in chronic HIV infection', AIDS Research and Human Retroviruses, 26, pp. 653 - 661, http://dx.doi.org/10.1089/aid.2009.0278
2010
Pett SL; Kelleher AD; Emery S, 2010, 'Role of interleukin-2 inpatients with HIV infection', Drugs, 70, pp. 1115 - 1130
2010
Pett SL; Emery S; Kelleher AD; Cooper DA, 2010, 'Antiretroviral agents: Focus on maraviroc for the treatment of HIV-1-infected adults', Clinical Medicine Insights: Therapeutics, 2, pp. 697 - 713, http://www.la-press.com/
2010
Pett SL; Emery S; Kelleher AD; Cooper DA, 2010, 'Antiretroviral agents: Focus on Maraviroc for the Treatment of HIV-1-Infected Adults', Clinical Medicine Insights: Therapeutics, 2, pp. CMT.S5420 - CMT.S5420, http://dx.doi.org/10.4137/cmt.s5420
2010
Zaunders J; Munier ML; Seddiki N; Pett SL; Ip S; Bailey M; Xu Y; Brown KJ; Dyer W; Kim MS; De Rose R; Kent SJ; Jiang L; Breit SN; Emery S; Cunningham AL; Cooper DA; Kelleher AD, 2009, 'High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40)', Journal of Immunology, 183, pp. 2827 - 2836, http://dx.doi.org/10.4049/jimmunol.0803548
2009
Seddiki N; Sasson SC; Santner-Nanan B; Munier M; Van Bockel DJ; Ip S; Marriott D; Pett SL; Nanan R; Cooper DA; Zaunders J; Kelleher AD, 2009, 'Proliferation of weakly suppressive regulatory CD4+ T cells is associated with over-active CD4+ T-cell responses in HIV-positive patients with mycobacterial immune restoration disease', European Journal of Immunology, 39, pp. 391 - 403, http://dx.doi.org/10.1002/eji.200838630
2009
Pett SL, 2009, 'Immunotherapies in HIV-1 infection', Current opinion in HIV & AIDS, 4, pp. 188 - 193
2009
Pett SL; Mccarthy M; Cooper DA; MacRae K; Tendolkar A; Norris R; Strizki J; Williams KM; Emery S, 2009, 'A Phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients', Antiviral Therapy, 14, pp. 111 - 115
2009
Pett SL; Zaunders J; Bailey M; Cooper DA; MacRae K; Emery S; Kelleher A, 2008, 'Changes in CCR5+ cells and antigen-specific CD4+ T-cells during monotherapy with a CCR5 antagonist SCH532706 compared with combination therapy', Journal of the International AIDS Society, 11, http://dx.doi.org/10.1186/1758-2652-11-s1-p297
2008
Boyd MA; Pett SL, 2008, 'Experimental and clinical pharmacology - HIV fusion inhibitors: a review', Australian Prescriber, 31, pp. 66 - 69
2008
Dyer W; Pett SL; Sullivan JS; Emery S; Cooper DA; Kelleher AD; Lloyd AR; Lewin S, 2007, 'Substantial improvements in performance indicators achieved in a peripheral blood mononuclear cell cryopreservation quality assurance program using single donor samples', Clinical and Vaccine Immunology, 14, pp. 52 - 59
2007
Stark D; Pett SL; Marriott D; Harkness JL, 2006, 'Post-kala-azar dermal leishmaniasis due to Leishmania infantum in a human immunodeficiency virus type 1-infected patient', Journal of Clinical Microbiology, 44, pp. 1178 - 1180
2006
Lifson A; Rhame F; Belloso WH; Dragsted U; El-Sadr W; Gatell J; Hoy JF; Krum E; Nelson R; Pedersen C; Pett SL; Davey R, 2006, 'Reporting and evaluation of HIV-related clinical endpoints in two multicenter international clinical trials', HIV Clinical Trials, 7, pp. 125 - 141
2006
Group* ER; Group: W; Pett SL; Wand H; Law MG; Arduino R; Lopez JC; Knysz B; Pereira LC; Pollack S; Reiss P; Tambussi G, 2006, 'Evaluation of Subcutaneous Proleukin (Interleukin-2) in a Randomized International Trial (ESPRIT): Geographical and Gender Differences in the Baseline Characteristics of Participants', HIV Research & Clinical Practice, 7, pp. 70 - 85, http://dx.doi.org/10.1310/hct.2006.7.2.005
2006
Pett SL; Wand HC; Law MG; Arduino R; Lopez JC; Knysz B; Pereira L; Pollack S; Reiss P; Tambussi G, 2006, 'Evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial (ESPRIT): Geographical and gender differences in the baseline characteristics of participants', HIV Clinical Trials, 7, pp. 70 - 85
2006
Samaras K; Pett SL; Gowers A; McMurchie M; Cooper DA, 2005, 'Iatrogenic Cushing`s syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: Six cases', Journal of Clinical Endocrinology and Metabolism, 90, pp. 4394 - 4398
2005
Pett SL; Williams LA; Day RO; Lloyd AR; Carr AD; Clezy KR; Emery S; Kaplan E; Mcphee D; Mclachlan AJ; Gelder F; Lewin S; Liauw WS; Williams KM, 2004, 'A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individuals', HIV Clinical Trials, 5, pp. 91 - 98
2004
Pett SL; Kelleher A, 2004, 'Antiretroviral therapy-induced immune restoration in HIV infection: A double-edged sword?', Expert Review of Anti-Infective Therapy, 2, pp. 335 - 339, http://dx.doi.org/10.1586/14787210.2.3.335
2004
Pett SL; Kelleher AD, 2003, 'Cytokine therapies in HIV-1 infection: Present and future', Expert Review of Anti-Infective Therapy, 1, pp. 83 - 96, http://dx.doi.org/10.1586/14787210.1.1.83
2003
Pett SL; Kelleher AD, 2003, 'Cytokine therapies in HIV-1 infection: present and future', Expert Review of Anti-Infective Therapy, 1, pp. 89 - 102
2003
O Loughlin AJ; Pett SL; Anderson D; Yorke J; Chua R; Williams DB; Hayward CS; Keogh AM; Macdonald PS; Cunningham PH, 2003, 'Cytomegalovirus polymerase chain reaction tests can replace endoscopy and biopsy for the initial diagnosis of cytomegalovrius gastrointestinal disease in patients following heart transplantation', CSANZ
2003
Pett SL; Dore GJ; Fielden R; Cooper DA, 2002, 'Cyclical hepatitis and early liver cirrhosis after hepatitis C seroconversion during pulsed antiretroviral therapy for primary HIV-1', AIDS, 16, pp. 2364 - 2365
2002
Pett SL; Emery S, 2001, 'Immunomodulators as adjunctive therapy for HIV-1 infection', Journal of Clinical Virology, 22, pp. 289 - 295, http://dx.doi.org/10.1016/S1386-6532(01)00201-3
2001
Suzuki K; Cunningham P; Harris C; Leas L; Zaunders J; Cooper DA; Kaufmann GR; Pett SL; Kelleher A; Mukaide M; Imai M; Kondo M; Finlayson R, 2001, 'Novel deletion of HIV type 1 reverse transcriptase residue 69 conferring selective high-level resistance to nevirapine', AIDS Research and Human Retroviruses, 17, pp. 1293 - 1296, http://dx.doi.org/10.1089/088922201750461366
2001
Pett SL; Milliken S, 2000, 'Current review of the metabolic and endocrine disturbances in human immunodeficiency virus infection', Current Opinion in Endocrinology & Diabetes, 7, pp. 96 - 101, http://dx.doi.org/10.1097/00075197-200004000-00009
2000
Pett SL; Milliken S, 2000, 'Current review of the metabolic and endocrine disturbances in human immunodeficiency virus infection', Current Opinion in Endocrinology and Diabetes, 7, pp. 96 - 101, http://dx.doi.org/10.1097/00060793-200004000-00009
2000
Flower B; Hung LM; McCabe L; Ansari MA; Le Ngoc C; Vo Thi T; Vu Thi Kim H; Nguyen Thi Ngoc P; Phuong LT; Quang VM; Trong TD; Le Thi T; Bao TN; Kingsley C; Smith D; Hoglund RM; Tarning J; Kestelyn E; Pett SL; van Doorn R; van Nuil JI; Turner H; Thwaites G; Barnes E; Rahman M; Walker AS; Day J; Van Vinh Chau N; Cooke GS, 2022, Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for Hepatitis C: a single arm mechanistic pilot study, , http://dx.doi.org/10.1101/2022.08.15.22278752
2022
Cooke GS; Pett S; McCabe L; Jones C; Gilson R; Verma S; Ryder SD; Collier JD; Barclay ST; Ala A; Bhagani S; Nelson M; Ch’Ng C; Stone B; Wiselka M; Forton D; McPherson S; Halford R; Nguyen D; Smith D; Ansari A; Dennis E; Hudson F; Barnes EJ; Walker AS, 2021, Strategic Treatment Optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C, , http://dx.doi.org/10.1101/2021.01.22.21250208
2021
Scott K; Chappell E; Mostafa A; Volokha A; Najmi N; Ebeid F; Posokhova S; Sikandar R; Vasylyev M; Zulfiqar S; Kaminskyi V; Pett S; Malyuta R; Karpus R; Ayman Y; Ahmed RHM; Hamid S; El-Sayed MH; Gibb D; Judd A; Collins IJ, 2021, Acceptability of Hepatitis C screening and treatment during pregnancy in pregnant women in Egypt, Pakistan and Ukraine, , http://dx.doi.org/10.1101/2021.09.29.21264171
2021
McCabe L; White IR; Chau NVV; Barnes E; Pett SL; Cooke GS; Walker AS, 2019, The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct acting antiviral Hepatitis C treatment strategies in Vietnam, , http://dx.doi.org/10.48550/arxiv.1911.02272
2019
Butler M; Tamborska A; Wood G; Ellul M; Thomas RH; Galea I; Pett S; Solomon T; Pollak T; Michael B; Nicholson T, Defining Causality in Neurological & Neuropsychiatric COVID-19 Vaccine Complications: What Have We Learnt from Current and Previous Vaccination Campaigns?, , http://dx.doi.org/10.2139/ssrn.3823441
Ross Russell A; Hardwick M; Jeyanantham A; White L; Deb S; Burnside G; Joy H; Smith C; Pollak T; Nicholson T; Davies NWS; Manji H; Easton A; Ray S; Zandi M; Coles JP; Menon D; Varatharaj A; McCausland B; Ellul M; Thomas N; Breen G; Keddie S; Lunn M; Al-Shahi Salman R; Carson A; Joyce E; Turner MR; Benjamin L; Solomon T; Kneen R; Pett S; Thomas RH; Michael B; Galea I, Spectrum, Risk Factors, and Outcomes of Neurological and Psychiatric Complications of COVID-19: A UK-Wide Cross-Sectional Surveillance Study, , http://dx.doi.org/10.2139/ssrn.3767901
Varatharaj A; Thomas N; Ellul M; Davies NWS; Pollak T; Tenorio EL; Sultan M; Easton A; Breen G; Zandi M; Coles JP; Manji H; Al-Shahi Salman R; Menon D; Nicholson T; Benjamin L; Carson A; Smith C; Turner MR; Solomon T; Kneen R; Pett S; Galea I; Thomas RH; Michael B, UK-Wide Surveillance of Neurological and Neuropsychiatric Complications of COVID-19: The First 153 Patients, , http://dx.doi.org/10.2139/ssrn.3601761
Davey RT; Fernandez-Cruz E; Markowitz N; Pett S; Babiker A; Wentworth D; Khurana S; Engen N; Gordin F; Jain MK; Kan V; Polizzotto MN; Riska P; Ruxrungtham K; Temesgen Z; Lundgren J; Beigel J; Lane HC; Neaton JD, Influenza Immunoglobulin for Adults Hospitalized with Influenza, , http://dx.doi.org/10.2139/ssrn.3365086
Grundmann A; Wu C-H; Hardwick M; Baillie JK; Openshaw P; Semple MG; Böhning D; Pett S; Michael B; Thomas RH; Galea I, Impact of Dexamethasone and Remdesivir on Neurological Complications during COVID-19, , http://dx.doi.org/10.2139/ssrn.4065552
Grundmann A; Hardwick M; Wu C-H; Semple MG; Böhning D; Pett S; Michael BD; Thomas RH; Galea I, Prevention of Neurological Complications During COVID-19: Protocol for a Retrospective Analysis of the ISARIC4C National Cohort, , http://dx.doi.org/10.2139/ssrn.4037376
Ray STJ; Abdel-Mannan O; Sa M; Fuller C; Wood GK; Psyden K; Yoong M; Ramas S; McCullagh H; Scott D; McMahon M; Thomas N; Taylor M; Vollmer B; Illingworth M; McCrea N; Davies V; Whitehouse W; Zuberi S; Guthrie K; Wassmer E; Shah N; Baker MR; Tiwary S; Petropoulos C; Vlachou V; Kinali M; Tan HJ; Varma U; Ram D; Avula S; Breen G; Enright N; Hassell J; Ross Russell AL; Kumar R; Mulholland RE; Pett S; Galea I; Thomas RH; Lim M; Hacohen Y; Solomon T; Griffiths MJ; Michael BD; Kneen R; Group CS, Neurological and Psychiatric Manifestations of COVID-19 in UK Children: A Prospective National Cohort Study, , http://dx.doi.org/10.2139/ssrn.3844784
Nugent D; Stirrup O; Pett S; Beddows S; Checchi M; Mesher D; Panwar K; Soldan K; Gilson R, 2019, 'P499 Human papillomavirus detection in residual samples from STI tests in men who have sex with men', in Poster Presentations, BMJ Publishing Group Ltd, presented at Abstracts for the STI & HIV World Congress (Joint Meeting of the 23rd ISSTDR and 20th IUSTI), July 14–17, 2019, Vancouver, Canada, http://dx.doi.org/10.1136/sextrans-2019-sti.580
2019
Land S; Tu E; Swenson L; Kelleher A; Kaye S; Pett SL; Emery S; Kaiser R; Silk D; Berthon-Jones N; Harrigan PR, 2013, 'Proviral DNA testing of HIV tropism in the Maraviroc Switch Collaborative Study (MARCH) - results of a three-phase quality assurance (QA) programme', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, CANADA, Toronto, pp. A144 - A144, presented at International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies, CANADA, Toronto, 04 June 2013 - 08 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335229500117&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2013
Polizzotto M; Van Bockel D; Law C; Roberts J; Buckland G; Just S; Comben S; Hillman R; Gilson R; Pett S; Poynten M; Law M; Kelleher A; Emery S, 2019, 'Clearance of HPV anal premalignant lesions and modulation of systemic immune responses to HPV oncogenes with low dose pomalidomide', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SWITZERLAND, Geneva, Vol. 30, presented at Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO), SWITZERLAND, Geneva, 11 December 2019 - 14 December 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000506799900104&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2019
Lukins TR; Pett SL; Brett J, 2013, Is it worth the weight?
2013
Tu E; Swenson LC; Land S; Pett S; Emery S; Marks K; Kelleher AD; Kaye S; Kaiser R; Schuelter E; Harrigan R, 2013, Reply to "issues on results of the external quality assessment for proviral DNA testing of HIV-1 tropism in the maraviroc switch collaborative study", http://dx.doi.org/10.1128/JCM.02207-13
2013
Pett SL; Emery S, 2010, 'Atazanavir', in Grayson ML; Crowe SM; McCarthy JS; Mills J; Mouton JW; Norrby SR; Paterson DL; Pfaller MA (ed.), Kucers' the use of antibiotics: A clinical review of antibacterial, antifungal, antiparasitic and antiviral drugs, edn. 6th, Hodder Arnold, London, pp. 2830 - 2841
2010
Pett SL; Post JJ, 2009, 'Mycobacterium tuberculosis', in Hoy J; Lewin S; Post JJ; Street A (ed.), HIV Management in Australasia: a guide for clinical care, edn. 2009, Australasian Society for HIV Medicine Inc., Darlinghurst, NSW, pp. 149 - 153
2009
Pett SL; Cooper DA, 2008, 'Classification and spectrum', in Mildvan D (ed.), International Atlas of AIDS, 4th ed., edn. Original, Springer, Philadelphia, PA, pp. 77 - 90
2008
Pett SL; Emery S; Cooper DA, 2006, 'Initial treatment of HIV-1 infection. Online access: www.antimicrobe.org', in Singh N; Swindells S; Shafer R (ed.), HIV Clinical Manual, edn. Original, ESun Technologies, LLC, online
2006
Aichelburg A; Pett SL; Cooper DA, 2002, 'AIDS as a World Health Problem', in AIDS as a World Health Problem, MacMillan Publishers, www.els.net, pp. 1 - 6
2002
Aichelburg A; Pett SL; Cooper DA, 2002, 'AIDS: Understanding HIV Transmission', in Encyclopedia of World Sciences, MacMillan Publishers, www.els.net, pp. 1 - 6
2002

  1. Emery S, Hoy J, Pett S, Roth N, NHMRC5688666 grant in support of the START study a Randomised trial to determine the safety and efficacy of early versus deferred treatment of adult HIV-infection. Role: Co-investigator. Award AUD405,401.00 over 2 years (2009-2011);

  2. Emery S, Matthews G, Hoy, J, Wright E, Pett S, NHMRC grant in support of the START study a Randomised trial to determine the safety and efficacy of early versus deferred treatment of adult HIV-infection. Role: Co-investigator. Award AUD $1,016,666.25 (2012-2017);

  3. INSIGHT. Funding agency: University of Minnesota. Grant: insight hin1v outpatient study flu 002 and h1n1v hospitalization study flu 003 (Sydney ICC). Start date: 01 Sep 2009 ongoing. Role: Chief Investigator (2009-2013); Award AUD400,000 (2009-2013);

  4.  INSIGHT. Funding agency: University of Minnesota. Grant name: insight hin1v outpatient study flu 002 and h1n1v hospitalization study flu 003 (Australia Site Coordinating Centre & flu pro). Start date: 01 Sep 2009 ongoing. Role: Chief Investigator (2009-2013); Award AUD400,000 (2009-2013). 

UCL grants since 2013:

As Chief Investigator

1) Independent Academic Grant from ViiV Healthcare, “A randomised study of maraviroc +/- metformin for hepatic steatosis in chronic HIV-1-infection (MAVMET)”; award £650,000 in November 2015 (duration of grant 3.5 years from May 2017).

2) Independent Academic Grant from Sysmex to conduct the SASA study: An observational study exploring the utility of the Sysmex-XN 20 analyser to assess lymphocyte subsets and other haematological parameters in chronic or acute viral infections; award £45,000 in April 2017 (duration of the grant 18 months). Role: Chief Investigator;

3) Anti-Influenza Hyperimmune Intravenous Immunoglobulin Clinical Outcome Study (FLU-IVIG) award USD250,000/year commenced 2014 ongoing until 2019. Role: Global Co-Chair; Chief Investigator of the FLU-IVIG study at the UK and Greece sites (n=10);

4) Investigator initiated study funded by Gilead Sciences. Understanding changes in regional bone turnover using 18F-PET/CT in HIV-1-infected men switching from EvipleraÒ (RPV/FTC/TDF) to Rilpivirine/Emtricitabine/Tenofovir Alafenamide (RPV/FTC/TAF) (PETRAM); award £284,000 in September 2016 (duration of the grant 3.5 years).

5) UK-India research collaboration to meet the challenges of tuberculosis (TB) research priorities in India. Global Challenges Research Fund Networking Grants, Academy of Medical Sciences. Awarded £23,493.32 March 2018-March 2019.

As Co-Applicant

1) Independent Academic Grant from ViiV Healthcare, “Observational study of fatty liver disease, a substudy of POPPY”. Independent Academic Grant from ViiV Healthcare; award £280,000 in September 2016 (duration of the grant 3 years).

2) STOP-HCV-1; EME award £1.4 million in Sep-2015 (duration of the grant 4 years).

3) Mechanisms underlying enhanced infection prophylaxis for advanced HIV in Africa. MRC Infections and Immunity Board (REF: MR/P022251/1); award £813,361 in April 2017 (duration of the grant 3 years).

4) SEARCH: South East Asian Research Collaboration in Hepatitis: SEARCH-2 VietnARMS study. Wellcome Trust. Collaborative Award in science 206296/Z/17/Z; award £3,786,213 (2018-2023) (duration of the grant 5 years).

5) UCL’s Global Engagement Funds 2017/18. £1688.

6) Metabolomic profile and clinical outcomes of adults hospitalized with influenza A. Role: Co-Applicant. Funding to support laboratory work (USD14,955) from NIAID, USA in October 2017;

7) HCVAVERT: designing a trial to cure hepatitis C virus (HCV) in HCV-infected pregnant women And prevent VERTical HCV transmission. MRC NIHR DfID Wellcome Global Health Trials Call 8 - Development grant. Funded 15-December-2017, sterling 150,000.

 

Clinical Research, HIV/AIDS, Immunology and Infectious Disease, Immunotherapy - large international clinical trials, of immune-based therapies and new therapeutic strategies for the treatment of HIV-1-infection in the developed and developing world; strategic approaches to shortening curative treatment for hepatitis C; the management of advanced HIV in the era of cART; interventional studies for influenza